BIO - Brazilian Information Oncology
@oncologybio
Group formed by 6 Brazilian oncologists with scientific excellence in taking care of patients.
ID: 1248341016882622465
http://www.bioeducation.com.br 09-04-2020 20:04:38
423 Tweet
626 Takipçi
309 Takip Edilen
Starting #GU23 with an outstanding review about 1L treatment of #RCC and an interesting spoiller about what we’ll see at #GU23 about #RCC with Maite Bourlon during a BIO - Brazilian Information Oncology meeting
Wonderful discussion!! BIO - Brazilian Information Oncology we have huge LATAM challenges André P. Fay Andrey Soares Fernando Sabino, MD, PhD 🌎👩🏻⚕️👨🏻⚕️
Congrats to Neeraj Agarwal, MD, FASCO for the interesting data and presentation of TALAPRO-2 trial. Talazoparib + Enzalutamide improve rPFS regardless HRR status. However OS benefit is pending and toxicity is a critical issue (72% G3/4 AE, 19% treatment discontinuation)… BIO - Brazilian Information Oncology #GU23
It still intriguing the positivity data from the non-HRR patients. Another important point is how these data are important for patients receiving a NHT in the mCSPC setting #GU23 BIO - Brazilian Information Oncology
Interesting data, but how many patients were PSA persistent (RTOG) and how many relapse after 6 months (GETUG-16)? Radical-HD has a mixture of them. How PSMA PET would change the stage in a high risk population? #GU23 BIO - Brazilian Information Oncology
Provocative and pragmatic discussion of Elena Castro regarding the data of TALAPRO-2 and TRITON-3 trials presented at ASCO #GU23. A final useful message/slide with all PARPi in different mCRPC treatment setting/scenario. BIO - Brazilian Information Oncology
A very important and practical question is: does have any patient who failed to ADT plus NHT in mHSPC that deserve PARPi combinations in the mCRPC scenario? #GU23 BIO - Brazilian Information Oncology
Interesting OS curve from PROPEL with a separation after 22 months, coincident with the rPFS. Is the post-progression therapy influencing this data? #GU23 BIO - Brazilian Information Oncology
Outstanding discussion about the best studies from #GU23 in a BIO - Brazilian Information Oncology meeting @DanielVargas_ Fernando Sabino, MD, PhD
Starting now the post #GU23 discussion with André P. Fay BIO - Brazilian Information Oncology
We are on line. Great debate in urothelial carcinoma and how to apply the evidences after #GU23 BIO - Brazilian Information Oncology @DanielVargas_ Fernando Sabino, MD, PhD
Amazing interactive discussion with the audience about the use of cisplatin or carboplatin after update of JAVELIN Bladder in the #GU23 BIO - Brazilian Information Oncology meeting @DanielVargas_ Fernando Sabino, MD, PhD Fabio Schutz André P. Fay Andre Sasse #karinetrindade
Is it time to triplet therapy for #RCC after #GU23? Maybe too early to detect who will benefit for this strategy BIO - Brazilian Information Oncology meeting Fabio Schutz ADRIANO G. e SILVA
Discussion about one of the best studies from #GU23. The importance of biomarkers to define who will or will not have benefit of chemotherapy in patients with CSI testicular cancer BIO - Brazilian Information Oncology meeting Andre Sasse
Controversies about therapies in mUC after #GU23. How many patients receive 1, 2 and 3L therapy? Do we need check FGFR for all? When? 3 or 6 cycles of chemo? Platinum eligibility. Cisplatin fit patients should receive cisplatin or carboplatin is acceptable? BIO - Brazilian Information Oncology meeting
Who are the mHSPC patients for triplet therapy after #GU23? Clinical and some pathological factors can help. Biomarkers are urgent. Could SPOP status help? BIO - Brazilian Information Oncology meeting André P. Fay #leonardoatem #karinetrindade
